← Human Trials & Peer-Reviewed Studies
Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,) in healthy male Korean adults.
Plain-language guide to PMID 24378207 (2014): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 24378207
- Journal
- Clinical therapeutics
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Jeon JY et al. (11 authors)
- DOI
- 10.1016/j.clinthera.2013.12.001
- Registered trial
- NCT01577849
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
A secondary objective was to evaluate the safety and tolerability of DP-R206 in healthy adult male Korean volunteers.
Why It Was Studied
Combined treatment with a bisphosphonate and vitamin D has been proposed for postmenopausal osteoporosis.
Who Took Part
The age groups tagged for this paper are young adults, adults and middle-aged adults, men only.
How the Study Was Run
The researchers set it up as a randomized, open-label and crossover study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.
Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.
Blood samples were collected from 24 hours' predose to 120 hours' postdose.
The plasma concentrations of vitamin D3 were analyzed by using a validated HPLC-MS/MS method.
What Was Measured
The subject headings attached to it are Bone Density Conservation Agents, Cholecalciferol, Diphosphonates, Drug Combinations, Ibandronic Acid, Republic of Korea and Tablets.
Author keywords: ibandronate, osteoporosis and vitamin D(3).
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (Clinical therapeutics), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.